ClinicalTrials.gg
Not yet recruitingNCT07951736Updated Nov 20, 2026

Posterior Default Network Modulation in Alcohol Use Disorder

A Phase 1 interventional study of Continuous theta burst stimulation (cTBS) and Intermittent theta burst stimulation (iTBS) in Alcohol Use Disorder, sponsored by Indiana University. Not yet recruiting at 1 site in United States. Open to participants aged 21 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by Indiana University · Phase 1, Interventional, and Basic science

How we know

Updated Nov 20, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
21 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 12 studies in Alcoholism by Indiana University — 4 open to participants now, 4 under way, none of them phase 3. Alcoholism · Indiana University.

Planned enrollment
7th of 12
70 · median 77
Started
2027
the only one that year
Phase 1
2 of 12
2 open now
Registered
12th of 12
by date

Among the 12 studies in Alcoholism by Indiana University, this one is the 7th largest by planned enrollment, is the only one that started in 2027, is one of 2 in phase 1, and was the 12th registered.

Alcoholism

1,679 studies on the registry are indexed under Alcoholism; 333 are open to participants now.

Browse Alcoholism studies →

Open to participants now

4 of the 12 studies in Alcoholism by Indiana University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 238 Alcoholism studies recruiting now, 85 (36%) set no upper age limit and 131 (55%) stop at 75 or younger; 9 take children under 18; 64 take healthy volunteers.

This study: 21 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Alcoholism by Indiana University, or all of them as a file.
02

Study summary

This proposal will test whether repetitive transcranial magnetic stimulation (rTMS) modulation of the brain's posterior default mode network (pDMN) will alter alcohol craving, alcohol seeking and impulsivity in men and women who have an alcohol use disorder but are not seeking treatment.

Read the detailed description

Alcohol use disorder is a common medical condition affecting the lives of individuals worldwide. Many receive no treatment and relapse is high in those who do; there is a clear need for new and more effective treatments. This project will test whether the pDMN, a large-scale brain circuit most active at rest, is a potential target for therapeutic interventions.

rTMS non-invasively modulates regional cortical activity. Theta burst stimulation (TBS) is a variant of rTMS that utilizes two common patterns, continuous (cTBS) and intermittent (iTBS). This project will test the ability of cTBS and iTBS to change pDMN function, and affect alcohol seeking, alcohol craving, and impulsivity. A sham TBS treatment will be used for comparison.

Sixty participants with mild to moderate alcohol use disorder, who are not seeking treatment, will undergo baseline characterization for alcohol cue responsivity and delay discounting. They will then undergo three experimental days, in random order: (i) sham TBS, (ii) continuous (cTBS), or (iii) intermittent (iTBS). TBS will be delivered twice each experimental day. In the morning, TBS will be followed by a functional magnetic resonance imaging (fMRI) session that includes testing brain responses to alcohol and other taste cues, and delay discounting. Blood oxygenation level dependent (BOLD) contrasts will assess changes within relevant brain structures and across functional brain circuits. In the afternoon, TBS will be followed by an alcohol self-administration session during which small intravenous infusions of alcohol can be earned on a progressive ratio schedule. Number of infusions earned will be used to assess changes in alcohol motivation after TBS treatment.

03

Conditions studied

  • Alcohol Use Disorder

Keywords

  • rTMS
  • TBS
  • Alcohol Seeking
  • Alcohol Craving
  • Delay Discounting
  • Alcohol Self-Administration
  • Impulsivity
04

Who can participate

Ages eligible
21 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and women aged 21 - 55
  • Alcohol Use Disorder diagnostic criteria based on Interview, Screening, and Measures of at least moderate severity
  • ≥7 or 14 drinks/week average over the last month or ≥ 3 or 4 drinks/occasion for women and men respectively
  • Positive alcohol cue reactivity screening
  • Systematic Delay Discounting behavior
  • Right-handed

Exclusion criteria

Exclusion Criteria:

  • Physical Exam, Vital Signs, , Laboratory Values, or screening assessment precluding safe participation or experimental procedures
  • Clinical Institute Withdrawal Assessment for Alcohol (CIWA) 177 ≥8 or reported significant risk symptoms
  • MRI
  • Pregnant or breast-feeding women; Women who do not attest to using accepted forms of
  • Current or desire for AUD or substance use treatment
  • Medical conditions (e.g., seizure disorder) that may influence participant safety or study outcome)
  • Positive urine drug screen for amphetamines/ methamphetamines, barbiturates, benzodiazepines, cocaine, opiates, or phencyclidine and evidence of intoxication
  • Medications or dosage changes (past 30 days) that could influence participant safety or data (e.g., antidepressants, antipsychotics, benzodiazepines, etc.) or interact with alcohol
  • Current/history of neurological disease of cerebral origin, head injury with > 20 min loss of consciousness, medical treatment impacting MRI data, or serious psychiatric illness (bipolar disorder, psychosis).
  • Positive BrAC reading precluding visit completion
  • Actively suicidal or are at serious suicidal risk
  • Left-handed or ambidextrous
  • First degree family member with seizure disorder
  • Inability to understand English study instructions
  • Intoxication from any substance terminates an experimental day and will be considered for overall exclusion or study participation.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
70 participants (estimated)

Study arms

  • Experimental
    Sequence 1

    On each of the three experimental study days, participants will undergo one of the following TBS treatment conditions: sham, continuous, or intermittent. Participants will receive all three treatment conditions in a randomly assigned order. To ensure participant blinding, the treatment order of this assigned sequence cannot be disclosed until the trial is concluded. An IV alcohol self-administration session is conducted on each study day. Use of IV alcohol solutions is allowed under an FDA IND. It is a research tool and is not being tested for clinical use.

    Other: Continuous theta burst stimulation (cTBS) · Other: Intermittent theta burst stimulation (iTBS) · Other: Sham TBS · Drug: IV alcohol solution

  • Experimental
    Sequence 2

    On each of the three experimental study days, participants will undergo one of the following TBS treatment conditions: sham, continuous, or intermittent. Participants will receive all three treatment conditions in a randomly assigned order. To ensure participant blinding, the treatment order of this assigned sequence cannot be disclosed until the trial is concluded. An IV alcohol self-administration session is conducted on each study day. Use of IV alcohol solutions is allowed under an FDA IND. It is a research tool and is not being tested for clinical use.

    Other: Continuous theta burst stimulation (cTBS) · Other: Intermittent theta burst stimulation (iTBS) · Other: Sham TBS · Drug: IV alcohol solution

Interventions

  • OtherContinuous theta burst stimulation (cTBS)

    cTBS consists of a continuous train of 3-pulse bursts of neurostimulation.

  • OtherIntermittent theta burst stimulation (iTBS)

    iTBS consists of 2 second trains of 3-pulse bursts of neurostimulation, alternating with 8 seconds of rest.

  • OtherSham TBS

    Sham TBS duplicates the peripheral sensations of TBS without neurostimulation

  • DrugIV alcohol solution

    Sterile alcohol is mixed with USP saline to a concentration of 6%

06

What researchers measure

Primary outcomes

  1. Change in pDMN BOLD responses to alcohol taste after iTBS, cTBS or sham treatment.

    During the fMRI scan, two taste tests will be run, one alternating brief exposures to a preferred alcohol beverage and water, and a second alternating a sports drink with water. The primary comparison will be BOLD contrast \[Flavor \> Water\] (where 'Flavor' is alcohol or sports drink) in the posterior default mode network (pDMN). Changes in response to alcohol-specific taste after iTBS, cTBS or sham treatments will be compared using linear or linear mixed models, controlling for age, biological sex, smoking, and subjective ratings (flavor liking and intensity, craving changes from baseline) and adjusting for multiple comparisons across regions.

    Time frame: 3 single day laboratory sessions scheduled 7-14 days apart

  2. Change in cue-induced craving after TBS.

    In the Alcohol Cue Reactivity screen (ACR), a participant rates their current craving for alcohol before and after a 3 minute exposure to their preferred alcohol beverage in its typical glass (looking, smelling and handling the glass but not drinking). The ACR will be conducted before and after the morning TBS treatment. Change in alcohol craving after cTBS, iTBS or sham treatments will be compared using a linear or linear mixed model.

    Time frame: 3 single day laboratory sessions scheduled 7-14 days apart

  3. Change in the number of completed trials and alcohol infusions earned on a progressive ratio task after TBS.

    During the alcohol infusion session, participants will be able to earn transient increases in infusion flow rate by completing a button pressing task. Number of trials required will increase after each earned infusion. The breakpoint is defined as the number of trials completed for the last infusion earned. Breakpoints after iTBS, cTBS and sham treatments will be compared using a linear or linear mixed model.

    Time frame: 3 single day laboratory sessions scheduled 7-14 days apart

  4. Change in impulsivity assessed using a delay discounting task after TBS.

    Delay discounting estimates impulsivity by measuring preference for immediate versus delayed rewards. To optimize the task for scanning, monetary values and starting delays will be based on an individual's performance on the task during the interview. Changes in impulsivity after cTBS, iTBS and sham treatments will be assessed using a linear or linear mixed model.

    Time frame: 3 single day laboratory sessions scheduled 7-14 days apart

  5. Change in pDMN BOLD responses during a delay discounting task after TBS.

    BOLD responses within the pDMN measured during the delay discounting task will be compared after cTBS, iTBS and sham treatments. Intervention (sham vs cTBS, and sham vs iTBS) and Group (sham-cTBS and sham-iTBS) contrasts will be assessed using linear or linear mixed models, controlling for age, biological sex, smoking, and subjective ratings (flavor liking and intensity, craving changes from baseline) and adjusting for multiple comparisons across regions.

    Time frame: 3 single day laboratory sessions scheduled 7-14 days apart

Secondary outcomes

  1. Change in pDMN functional connectivity during alcohol tasting after TBS treatment.

    In separate scans, brief exposures to a preferred alcohol beverage or a sports drink will be alternated with water. Functional network connectivity will be assessed by calculating changes in the correlation between pairs of nodes within the pDMN.

    Time frame: 3 single day laboratory sessions scheduled 7-14 days apart

  2. Change in functional connectivity between the pDMN and salience network after TBS.

    The effect of TBS treatments on functional network connectivity will be assessed by calculating changes in the correlation between pairs of nodes within the pDMN and the salience network. The difference in connectivity estimates after cTBS, iTBS and sham TBS will be assessed using linear mixed models.

    Time frame: 3 single day laboratory sessions scheduled 7-14 days apart

  3. Change in within-DMN functional connectivity during a delay discounting task after TBS.

    During the delay discounting task, functional connectivity will be estimated from regional BOLD time series using Pearson correlations. Pairwise connectivity estimates will be computed for predefined region of interest pairs within the pDMN. The difference in connectivity estimates after cTBS, iTBS and sham TBS will be assessed using linear mixed models.

    Time frame: 3 single day laboratory sessions scheduled 7-14 days apart

  4. Change in functional connectivity between the pDMN and cognitive control areas after TBS.

    Exploratory assessments will be conducted to detect other potentially important effects of TBS on connectivity between the pDMN and cognitive control areas. Contrasts between cTBS and iTBS will be compared during delay discounting and alcohol tasting.

    Time frame: 3 single day laboratory sessions scheduled 7-14 days apart

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — We will contribute date to the National Data Archive as required by NIH. The final raw dataset will be available to other researchers when we have collected all subjects and completed our own planned analyses. Prior to completion of our own planned analyses, we would be willing to consider releasing the dataset upon request. We will work with our IRB to establish a strategy for de-identifying the data while retaining the ability to ensure the quality of the stored data.

Supporting information: Study protocol, Informed consent form

Time frame: After all subjects have been collected and the primary outcomes accepted for publication. The dataset will be available indefinitely,

Access criteria: On request to the PIs

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2027; primary completion for Jun 2031, 53 months later.

Of 63 non-industry phase 1 interventional studies under Alcoholism, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 49. This study's planned 53 months is above that.

Counting every sponsor, half of 75 studies reached it within 28 months; a quarter within 19 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2026
First posted
Nov 20, 2026
StartEst.
Jan 2027
Primary completionEst.
Jun 2031
CompletionEst.
Jun 2031
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07951736
Lead sponsor
Indiana University
Responsible party
Martin Plawecki (Associate Professor of Psychiatry, Indiana University) — Principal investigator
First posted
Nov 20, 2026
Start date
Jan 2027 (estimated)
Primary completion
Jun 2031 (estimated)
Completion
Jun 2031 (estimated)
Last update
Nov 20, 2026

Study contacts

Ann E Kosobud, PhD
Contact
akosobud@iu.edu
3172740087
James M Hays
Contact
haysjm@iu.edu
3179486550
Martin H Plawecki, MD, PhD
principal investigator · Department of Psychiatry, Indiana University School of Medicine
David Kareken, PhD
principal investigator · Department of Neurology, Indiana University School of Medicine

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion